This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

West Pharmaceutical Services Inc (WST)

NYSE: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 1.42B 1.37B 1.27B 1.19B
Cost of Sales 883.60M 848.50M 801.80M 777.30M
Gross Operating Profit 537.80M 519.90M 464.60M 415.00M
Selling, General, and Administrative Expenses 228.70M 234.90M 218.10M 191.10M
Research & Development 37.30M 37.90M 33.20M 29.10M
Operating Income before D & A (EBITDA) 271.80M 247.10M 213.30M 194.80M
Depreciation & Amortization 90.00M 85.20M 76.90M 75.70M
Interest Income 3.50M 1.90M 1.80M 1.30M
Other Income - Net 6.20M 5.20M -6.80M 6.30M
Special Income / Charges -700.00K 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) 190.80M 169.50M 130.10M 117.20M
Interest Expense 16.50M 17.00M 16.70M 18.20M
Pre-Tax Income 174.30M 152.50M 113.40M 99.00M
Income Taxes 47.20M 40.20M 32.70M 23.50M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 127.10M 112.30M 80.70M 75.50M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 127.10M 112.30M 80.70M 75.50M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 127.10M 112.30M 80.70M 75.50M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
127.80M 111.80M 82.00M 85.00M
Preferred Dividends
Net Income Available To Common 127.10M 112.30M 80.70M 75.50M
Basic EPS from Continuing Ops. 1.79 1.61 1.19 1.12
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 1.79 1.61 1.19 1.12
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 1.79 1.61 1.19 1.12
Basic Normalized Net Income/Share 1.80 1.61 1.21 1.26
EPS fr Continuing Ops. 1.75 1.57 1.12 1.02
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 1.75 1.57 1.12 1.02
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.03 0.06
EPS, Total 1.75 1.57 1.15 1.08
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
1.76 1.57 1.14 1.15
Dividends Paid per Share 0.41 0.39 0.37 0.35
WST News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

WST West Pharmaceutical Services Inc

Chart of WST

Analysts Ratings for WST

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 1 1
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET WST ANALYST REPORT

WST Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs